TKISThyssen Krupp Information Services (Thyssen Krupp Materials & Services)
TKISThe Kilmore International School (Kilmore, Victoria, Australia)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Wound healing did not appear to be a notable problem following surgery and NAT with TKIs, provided that the TKI treatment was discontinued for a sufficient length of time before surgery.
This is the first time that a compound has demonstrated in a controlled study, a clinically meaningful improvement in PFS in patients with NSCLC who have progressed on first generation EGFR TKIs.
Sorafenib and sunitinib, two TKIs already marketed for other malignancies, are seeing growing off-label use in patients with locally advanced or metastatic papillary or follicular thyroid cancer.
Hochmair, Medical Pulmonologist, Department of Internal Medicine and Pneumology, Krankenhaus Nord, Klinik Floridsdorf and coordinating investigator in the study said, 'As many patients with this type of lung cancer eventually acquire resistance to EGFR TKIs, it's important to consider the order of these therapies to provide patients with as many future treatment options as possible.
The European Commission has granted conditional marketing authorisation for Pfizer's LORVIQUA as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy, or crizotinib and at least one other ALK TKI, it was reported yesterday.
Erythrocytosis due to VEGFR TKIs was first reported by Alexandrescu et al in 2008.
Dasatinib, a second-generation tyrosine kinase inhibitor (TKI), has profoundly improved the prognosis for Philadelphia chromosome-positive leukemia [1].
Researchers found that of 106 patients who started tyrosine kinase inhibitors (TKIs) for advanced lung cancer, one-quarter with the highest out-of-pocket costs died sooner: They were more than twice as likely to have died three months after beginning treatment, than patients with the lowest personal costs.
Health benefits of tyrosine kinase inhibitors and focus of companies on expanding indications of existing and pipeline TKIs are major drivers of the global Tyrosine Kinase Inhibitors Market.